Empreendimentos Pague Menos SA
Empreendimentos Pague Menos SA operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceutical products and related consumer goods.
Business. Empreendimentos Pague Menos SA (PGMN3.SA) is a drug retailer operating within the Food & Drug Retailing industry. The company is headquartered in Brazil and is primarily listed on the B3 (São Paulo) stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
5 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Empreendimentos Pague Menos SA (PGMN3.SA) is a drug retailer operating within the Food & Drug Retailing industry. The company is headquartered in Brazil and is primarily listed on the B3 (São Paulo) stock exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Empreendimentos Pague Menos SA maintains a debt-to-equity ratio of 1.2, indicating a moderate level of leverage, while its liquidity position is characterized as medium, with a current ratio of 1.59. The company's free cash flow of 349.4 million BRL supports its operational flexibility, although its net cash position is negative after accounting for total debt.
In terms of profitability, the company's return on equity (ROE) is 8.44%, which is a measure of how effectively it generates profit from shareholders' equity. Its return on assets (ROA) is 2.62%, suggesting that the company is generating a relatively modest return on its total asset base.
The company's revenue is concentrated in the drug retailing segment, with no disclosed geographic diversification. This concentration may expose the company to specific market risks, although the exact nature of these risks is not quantified in the available data.
Looking at the growth trajectory, the company's revenue for the latest period is 14.9 billion BRL. While the outlook for the current and next fiscal years is not explicitly provided, the company's operating income of 861.17 million BRL and net income of 260.28 million BRL suggest a stable financial performance.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash is negative after subtracting total debt, which could affect its ability to meet short-term obligations without additional financing.
Recent events, such as analyst estimates, show a mean price target of 7.24 BRL and a median price target of 7.99 BRL. The mean recommendation from analysts is 2.40, indicating a generally positive outlook, with four buy recommendations and no strong buy or hold recommendations.
- The company has a moderate level of leverage with a debt-to-equity ratio of 1.2.
- It maintains a current ratio of 1.59, indicating a medium liquidity position.
- The company's ROE is 8.44%, suggesting effective use of shareholders' equity.
- Analysts have a generally positive outlook, with a mean recommendation of 2.40 and four buy recommendations.
- The company's net cash is negative after accounting for total debt, which could impact its liquidity.
- **margin_outlook_rationale**: The company's gross profit margin is 31.95%, which is a key indicator of its profitability and cost management efficiency.
- **rd_outlook_rationale**: The company's R&D outlook is not explicitly provided, but its focus on drug retailing suggests ongoing investment in product offerings and customer service.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,53 |
| Revenue | —no estimate | —no estimate | 17,2B BRL |
| Operating income | —no estimate | —no estimate | 946,5M BRL |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Empreendimentos Pague Menos SA Market data — financials · 2026-05-28
- Empreendimentos Pague Menos SA Market data — analyst estimates · 2026-05-28